Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||TransCon TLR7/8 Agonist|
|Synonyms||Resiquimod Hydrogel-based Sustained-release formulation|
TransCon TLR7/8 Agonist is a hydrogel based formulation of an imidazoquinolinamine and resiquimod, which acts as an agonist of TLR 7 and TLR8, which potentially activates the antitumor immune response and may lead to tumor cell lysis (NCI Drug Dictionary).
|DrugClasses||TLR7 Agonist 8 TLR8 Agonist 7|
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Pembrolizumab + TransCon TLR7/8 Agonist||Pembrolizumab TransCon TLR7/8 Agonist||0||1|
|TransCon TLR7/8 Agonist||TransCon TLR7/8 Agonist||0||1|